D. Boral Capital Reiterates Buy Rating for Avita Medical (NASDAQ:RCEL)

Avita Medical (NASDAQ:RCEL)‘s stock had its “buy” rating reissued by D. Boral Capital in a note issued to investors on Friday,Benzinga reports. They currently have a $14.00 price target on the stock. D. Boral Capital’s price target would suggest a potential upside of 250.88% from the company’s previous close.

Other equities research analysts have also recently issued research reports about the company. Wall Street Zen cut Avita Medical from a “hold” rating to a “sell” rating in a report on Saturday, August 9th. Lake Street Capital cut Avita Medical from a “buy” rating to a “hold” rating and lowered their target price for the company from $8.00 to $4.00 in a research note on Friday. Weiss Ratings restated a “sell (d-)” rating on shares of Avita Medical in a research note on Wednesday, October 8th. Finally, BTIG Research cut Avita Medical from a “neutral” rating to a “sell” rating and set a $3.00 target price for the company. in a research note on Friday, August 8th. Two research analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Avita Medical currently has an average rating of “Hold” and an average target price of $10.80.

Avita Medical Stock Performance

NASDAQ RCEL opened at $3.99 on Friday. Avita Medical has a fifty-two week low of $3.60 and a fifty-two week high of $14.16. The stock has a 50 day simple moving average of $5.08 and a two-hundred day simple moving average of $6.14. The stock has a market cap of $106.21 million, a P/E ratio of -2.03 and a beta of 1.64.

Avita Medical (NASDAQ:RCEL) last released its quarterly earnings data on Thursday, August 7th. The company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.12). Avita Medical had a negative return on equity of 632.62% and a negative net margin of 68.87%.The business had revenue of $18.42 million during the quarter, compared to analysts’ expectations of $34.27 million. Avita Medical has set its FY 2025 guidance at EPS. Sell-side analysts predict that Avita Medical will post -0.95 earnings per share for the current year.

Insider Activity at Avita Medical

In other news, Director Robert Mcnamara bought 10,000 shares of the stock in a transaction dated Thursday, August 28th. The stock was bought at an average price of $4.50 per share, for a total transaction of $45,000.00. Following the purchase, the director directly owned 86,771 shares in the company, valued at $390,469.50. This trade represents a 13.03% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last three months, insiders purchased 24,000 shares of company stock valued at $113,660. Company insiders own 2.80% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Farther Finance Advisors LLC bought a new position in Avita Medical during the 3rd quarter valued at approximately $32,000. CWM LLC increased its position in Avita Medical by 1,099.5% during the 1st quarter. CWM LLC now owns 4,918 shares of the company’s stock valued at $40,000 after buying an additional 4,508 shares in the last quarter. GAMMA Investing LLC increased its position in Avita Medical by 688.9% during the 1st quarter. GAMMA Investing LLC now owns 6,374 shares of the company’s stock valued at $52,000 after buying an additional 5,566 shares in the last quarter. Meeder Asset Management Inc. bought a new position in Avita Medical during the 1st quarter valued at approximately $53,000. Finally, The Manufacturers Life Insurance Company bought a new position in Avita Medical during the 2nd quarter valued at approximately $58,000. Institutional investors own 27.66% of the company’s stock.

Avita Medical Company Profile

AVITA Medical, Inc, together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions.